Acquisition of CorHepta - Schedule of Allocation of Consideration Transferred (Details) - USD ($)		3 Months Ended
	Feb. 21, 2025	Mar. 31, 2026
Fair Value, Recurring [Member]
Business Combination [Line Items]
Fair value of consideration		$ 7,338,719
CorHepta Pharmaceuticals [Member]
Business Combination [Line Items]
Cash		49,633
Current liabilities		(68,208)
Fair value of consideration		7,400,000
CorHepta Pharmaceuticals [Member] | In Process Research and Development [Member]
Business Combination [Line Items]
Acquired IPR&D		$ 7,357,294
CorHepta Pharmaceuticals [Member] | Fair Value, Recurring [Member]
Business Combination [Line Items]
Fair value of consideration	$ 7,338,719